Bullish Potential Visualized: Sucampo Pharma (SCMP), NantKwest (NK), vTv Therapeutics (VTVT), Tuesday Morning (TUES)
Brokerage firm H.C. Wainwright has initiated coverage on shares of Sucampo Pharmaceuticals, Inc. (SCMP) with a Buy rating and a price target of $31.00
Early this month, Sucamporeported for the second quarter 2015 revenue of $34.9 million, a 45% increase year over year, and net income of $9.6 million, or $0.21 per diluted share, compared to net income of $1.6 million, or $0.04 per diluted share in the same quarter the prior year.
The company increased its earnings guidance for full year 2015 and now expects GAAP net income to be in the range of $30.0 million to $35.0 million, or $0.65 to $0.75 per diluted share for the period
Sucampo Pharmaceuticals, Inc. (SCMP) is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide.
Investment analysts at MLV & Co initiated coverage on NantKwest, Inc. (NK) stock with a Buy rating and a price target of $35.00
NantKwest recently announced the closing of its initial public offering of 9,531,200 shares of common stock at a price to the public of $25.00 per share, generating approximately $222.5 million in net proceeds after deducting the underwriting discounts and commissions and other offering expenses.
NantKwest, Inc. (NK) is a a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases
Brokerage and investment banking firm Stifel Nicolaus has initiated coverage on shares of vTv Therapeutics Inc. (VTVT) with a Buy rating and a price target of $17.00
vTv Therapeutics commenced on The Nasdaq Stock Market on July 30, 2015. The pricing of its initial public offering of 7,812,500 shares of its Class A common stock was at a price to the public of $15.00 per share.
vTv Therapeutics Inc. (VTVT) is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.
Tuesday Morning Corp. (TUES) was upgraded by equities researchers at Stifel Nicolaus from Hold to Buy, with a price target of $9.00 per share
Last week, Tuesday Morning reported fourth quarter fiscal 2015 net sales of $213.0 million and a non-GAAP net loss of ($4.2) million, or ($0.10) per share for the period
Tuesday Morning Corp. (TUES) is a leading off-price retailer specializing in selling deeply discounted, upscale decorative home accessories, housewares, seasonal goods and famous-maker gifts.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer